TNGX

TNGX

USD

Tango Therapeutics Inc.

$8.010+0.120 (1.521%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$7.890

Hoch

$8.170

Tief

$7.470

Volumen

2.98M

Unternehmensfundamentaldaten

Marktkapitalisierung

1.1B

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

2.68M

Börse

NGM

Währung

USD

52-Wochen-Spanne

Tief $1.03Aktuell $8.010Hoch $9.7

Ähnliche Nachrichten

GlobeNewswire

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S.

Mehr anzeigen
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Analyst Upgrades

Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12

Guggenheim analyst Charles Zhu maintains Tango Therapeutics with a Buy and raises the price target from $10 to $12.

Mehr anzeigen
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12
GlobeNewswire

Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,

Mehr anzeigen
Tango Therapeutics Announces $225 Million Financing
GlobeNewswire

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49%

Mehr anzeigen
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers